Novo setback casts doubt on a new way to treat heart disease

Ziltivekimab's failure in a key trial spurred share sell-offs for Novo and other biotechs, as it suggested trouble for different cardiovascular drugs that also target inflammation.

By Jonathan Gardner • July 31, 2026

MapLight dives despite positive data for schizophrenia drug

Shares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not competitive with Bristol Myers' Cobenfy.

By Jacob Bell • July 27, 2026

Explore the Trendline➔

Vaccine development

Vaccine developers are investing in shots for RSV, influenza and pneumococcal disease in a newly uncertain regulatory climate.

By BioPharma Dive staff

[Podcast] From Protocol to Patient: Inside Clinical Supply with Almac Clinical Services

This podcast explores how clinical trial supplies move from early planning to global delivery, ensuring investigational medicines reach patients safely and on time.

By BioPharma Dive's studioID • Updated May 26, 2026

[Podcast] (Season 2) The Progress Profile: Alzheimer’s Research in Focus

This podcast explores how leading Alzheimer’s experts are working to bridge the gap between clinical trial design and frontline care.

By BioPharma Dive's studioID • July 27, 2026

Lilly, with new data, to seek FDA approval of obesity drug retatrutide

The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions about the additive benefits a “triple-G” drug has on heart health.

By Kristin Jensen • July 23, 2026

Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug

To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it competitive with a rival Ionis therapy.

By Jacob Bell • July 22, 2026

Agios scraps sickle cell drug

The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s frustrated drugmakers of late.

By Jacob Bell • July 21, 2026

GSK shelves cough drug acquired in $2B deal

Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class to fail.

By Jonathan Gardner • July 17, 2026

How well are AI-discovered drugs faring in the clinic?

Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted development.

By Kelly Bilodeau • July 17, 2026

Veradermics keeps ‘momentum going’ as baldness drug helps women with hair loss

The Phase 2 data exceeded expectations, lifting company shares as high as nearly $130 apiece and building the case for what may be the first pill specifically approved for female pattern hair loss.

By Kristin Jensen • July 16, 2026

Merck ADC, in China study, shows potential to replace chemo in lung cancer

The results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone,” could be part of a future treatment standard for front-line lung cancer. 

By Kristin Jensen • July 15, 2026

Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs

The study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why higher doses didn’t perform better.

By Jacob Bell • July 14, 2026

Freenome colorectal cancer test data improve on earlier results

The new study results could make Abbott, which has an agreement with Freenome to market the blood-based test, the dominant player in colorectal cancer screening, Evercore ISI analysts said.

By Susan Kelly • July 13, 2026

Q32 bounces back to claim study success for alopecia drug

Nearly two years after clinical setbacks cratered Q32’s stock price, new results showed hair growth improvements that surpassed investors’ expectations. 

By Jonathan Gardner • July 13, 2026

GSK, Hansoh ADC extends survival in lung cancer study

GSK claimed the result was a first for an ADC aimed at the “B7-H3” protein, an increasingly popular target of late among cancer drugmakers. 

By Delilah Alvarado • July 10, 2026

Roche scraps two Ionis-partnered Huntington’s drugs

The Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of a second drug was scrapped because of a safety signal in animal testing.

By Jonathan Gardner • July 9, 2026

HHS plan to speed drug research won’t remove ‘self-inflicted’ delays

U.S. clinical trials continue to lose ground to China, but is Operation Trialblazer enough to help America catch up?

By Kelly Bilodeau • July 9, 2026

AstraZeneca, Ionis drug fails big heart disease study in major setback

Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and boosted the outlook of rival drugs from Alnylam and BridgeBio Pharma.

By Ben Fidler • July 9, 2026

Kailera says obesity pill succeeds in late-stage trial in China

The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side effects that “alarmed” one analyst.

By Jonathan Gardner • July 7, 2026

Beyond Boston: Unlikely cities stake biotech claims

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.

By Alexandra Pecci • July 6, 2026

BridgeBio gets funding for drug launch; United buys into cell therapy

Elsewhere, Otsuka’s kidney drug hit the goal of a confirmatory trial and Vertex’s CRISPR sickle cell drug secured expanded approval.

By BioPharma Dive staff • July 1, 2026

Abivax shares surge as worries subside over immune drug’s cancer risk

According to Abivax, fresh data suggest malignancy rates in its trials were no higher than "background" ones for people with ulcerative colitis, clearing a key safety concern.

By Jonathan Gardner • July 1, 2026

10 clinical trials to watch in the second half of 2026

The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.

By BioPharma Dive staff • June 29, 2026

FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services

Replimune’s application is the latest example of changing attitudes at the FDA. Elsewhere, Revolution Medicines outlined more RAS-blocking data and a Definium stock offering brought in $800 million.

By BioPharma Dive staff • June 26, 2026

On second try, Acadia drug gets nod from European regulators

The influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the marketing authorization for Tavneos be revoked.

By Jonathan Gardner • June 26, 2026